Clin Pharmacol Ther 1998 Dec;64(6):636-47
A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride.
Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO
Division of Clinical Pharmacology, GlaxoWellcome Research and Development, Middlesex, England. po7205@GlaxoWellcome.co.uk
OBJECTIVE: To develop a pharmacokinetic-pharmacodynamic model that characterizes the conversion of testosterone to dihydrotestosterone (DHT) by 5 alpha-reductase types 1 and 2 and the irreversible inhibition of 5 alpha-reductase by finasteride, a 5 alpha-reductase type 2 inhibitor and by GI198745 (dutasteride), a potent and specific dual 5 alpha-reductase inhibitor.
Healthy men (n = 48) received doses of 0.1 to 40 mg GI198745 (n = 4 subjects per dose), 5 mg finasteride (n = 8), or placebo (n = 8) in a parallel-group study. Plasma concentrations of GI198745, finasteride, and DHT were measured frequently up to 8 weeks after dosing. Models were fitted with mixed-effects modeling with the NONMEM program.
RESULTS: The pharmacodynamics were
well described with a model that accounted for the rates of DHT formation and elimination,
5 alpha-reductase turnover, relative capacity of the 2 5 alpha-reductase isozymes, and the
rates of irreversible inhibition of one (finasteride) or both (GI198745) types of 5
alpha-reductase. The model indicated that type 2 5 alpha-reductase contributed
approximately 80% of plasma DHT. GI198745 was about 3-fold more potent than finasteride on
5 alpha-reductase type 2. Nearly full blockade of both isozymes was achieved at doses of
10 mg or more GI198745, although the potency of this agent on 5 alpha-reductase type 1 was
less than on type 2.
CONCLUSIONS: A physiologically based model for the turnover and irreversible inhibition of 5 alpha-reductase and for formation and elimination of DHT described the data well. This model helps explain differences in the rates of onset and offset of effect and offers a way to determine the relative potency of the irreversible 5 alpha-reductase inhibitors.